Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 2, 2006, Pages 576-578

  Moeremans, K ^a   Annemans, L ^a,b  

^a Health Economics and Disease Management   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Adjuvant; Anastrozole; Breast cancer; Cost effectiveness

Indexed keywords

ANASTROZOLE; HORMONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DISEASE COURSE; FOLLOW UP; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NITRILES; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 33748760878     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00699.x     Document Type: Conference Paper

References (8)

1. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
2. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. 1998;13:397-409.
3. Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002;8:81-7.
4. Bonneterre J, Buzdar A, Nabholtz JMA et al. Anastrozole is superior to tamoxifen as first line therapy of hormone receptor positive advanced breast carcinoma. Results of two randomised trials 2001 designed for combined analysis. Cancer 2001;92:2247-58.
5. Chang J, Clark G, Allred D, Mohsin S, Chamness G, Elledge R. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-53.
6. Karnon J, Jones T. A stochastic economic evaluation of letrozole versus tamoxifen as a first line hormonal therapy. Pharmacoeconomics 2003;21:513-25.
7. Cocquyt V, Moeremans K, Annemans L, Clarys P, Van Belle S. Long-term medical costs of postmenopausal breast cancer therapy. Ann Oncol 2003;14:1057-63.
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.